Impact on health-related quality of life of the addition of bevacizumab to cisplatin-pemetrexed in malignant pleural mesothelioma in the MAPS phase III trial.

Virginie Westeel,Guillaume Eberst,A. Anota,Arnaud Scherpereel,Julien Mazieres,Jacques Margery,L. Greillier,Clarisse Audigier Valette,Denis Moro-Sibilot,Olivier Molinier,Lena Herve,F. Rivière,Isabelle Monnet,V. Gounant,H. Janicot,Radj Gervais,C. Locher,Franck Morin,Gérard Zalcman,French Cooperative Thoracic Intergroup

Impact on health-related quality of life of the addition of bevacizumab to cisplatin-pemetrexed in malignant pleural mesothelioma in the MAPS phase III trial.

2018

8505Background: The IFCT-GFPC-0701 MAPS phase III trial highlighted a significant improvement in overall survival with the addition of bevacizumab to the standard first-line chemotherapy regimen, c...

Keywords:

Pemetrexed
Bevacizumab
Cancer research
Physical therapy
Mesothelioma
Cisplatin
Medicine
overall survival
pleural mesothelioma
Oncology
health related quality of life
Internal medicine
Chemotherapy regimen
Pathology

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations